Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2601 to 2650 of 8236 results

  1. Cefepime–enmetazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia TS ID 12035

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Entrectinib for treating NTRK fusion-positive solid tumours in people 1 month to 11 years [TSID12116]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Zanubrutinib for Chronic lymphocytic leukaemia (CLL) or Follicular lymphoma or Marginal zone lymphoma (MZL) or Waldenstrom's macroglobulinaemia [ID12199]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Risankizumab for treating moderate to severe plaque psoriasis in people 6 to 17 years [TSID12204]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. AI in retinal scanning MT524 (MIB265)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  6. PROPEL (mometasone furoate implant, 370ug) MT578 (MIB253)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  7. MTEP - Routing Butterfly IQ ultrasound scanner MT635 (MIB254)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  8. Kodex EPD system MT575 (MIB260)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  9. URO17 for testing suspected bladder cancer

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  10. The Stak for knee stretching following knee replacement or injury or to treat osteoarthritis

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  11. CytoSorb for reducing risk of bleeding during cardiac surgery

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  12. DOASENSE DOAC dipstick product for the detection of direct oral anti-coagulants

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  13. FebriDx for C-reactive protein and myxovirus resistance protein A testing

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  14. Actim Pancreatitis for diagnosing acute pancreatitis

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  15. Archimedes for biopsy of suspected lung cancer

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  16. Cor-Knot for tying suture knots in valve surgery

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  17. Liposomal bupivacaine for treating postoperative pain [ID3799]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  18. Zilurgisertib for preventing new heterotopic ossification lesions caused by fibrodysplasia ossificans progressiva in people 12 years and over [ID6637]

    Awaiting development Reference number: GID-TA11840 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  19. Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]

    Awaiting development Reference number: GID-TA11758 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  20. Statement of intent on NICE's approach to ongoing evaluations ahead of proposed changes to NICE's standard cost-effectiveness thresholds: nice general consultation

    We are listening to your views on this NICE general. Comments close 30 January 2026.

    NICE guideline
    In consultation

  21. Kidney Cancer Quality Standard

    In development Reference number: GID-QS10186 Expected publication date:  19 March 2026

    Quality standard
    In development

  22. Rare diseases

    In development Reference number: GID-QS10197 Expected publication date:  27 February 2026

    Quality standard
    In development

  23. DB-OTO for Hearing loss [TSID12321]

    Awaiting development Reference number: GID-TA11911 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  24. Etavopivat for treating sickle cell disease in people 12 years and over [TSID12320]

    Awaiting development Reference number: GID-TA11912 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  25. Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [TSID12315]

    Awaiting development Reference number: GID-TA11913 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  26. Perioperative care in adults

    In development Reference number: GID-QS10094 Expected publication date:  01 July 2026

    Quality standard
    In development

  27. Luspatercept for Anaemia due to myelodysplastic syndromes [TSID12310]

    Awaiting development Reference number: GID-TA11914 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  28. Luspatercept for treating anaemia caused by myelofibrosis [TSID12309]

    Awaiting development Reference number: GID-TA11915 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  29. Domestic Abuse: draft scope consultation

    We are listening to your views on this NICE guideline. Comments close 27 January 2026.

    NICE guideline
    In consultation

  30. Orforglipron for treating obstructive sleep apnoea associated with obesity or overweight [TSID12323]

    Awaiting development Reference number: GID-TA11916 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  31. Riliprubart for treating chronic inflammatory demyelinating polyneuropathy [TSID12314]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  32. Peginterferon alfa-2a for treating polycythaemia vera or essential thrombocythaemia [TSID12325]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  33. Ravulizumab for treating primary IgA nephropathy [TSID12313]

    Awaiting development Reference number: GID-TA11919 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  34. Semaglutide 7.2 mg single-dose device for managing overweight and obesity [TSID12324]

    Awaiting development Reference number: GID-TA11920 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  35. Setrusumab for treating osteogenesis imperfecta [TSID12308]

    Awaiting development Reference number: GID-TA11921 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  36. Tirzepatide for managing overweight and obesity in people 12 to 17 years [TSID12322]

    Awaiting development Reference number: GID-TA11923 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  37. Zasocitinib for treating moderate to severe plaque psoriasis [TSID12318]

    Awaiting development Reference number: GID-TA11926 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  38. Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]

    In development Reference number: GID-TA11774 Expected publication date:  30 September 2026

    Technology appraisal guidance
    In development

  39. Galcanezumab for migraine [TSID10663]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  40. Bevacizumab (Avastin and biosimilars) with fluoropyrimidine-based chemotherapy for untreated metastatic colorectal cancer [ID6465]

    Awaiting development Reference number: GID-TA11703 Expected publication date:  04 February 2026

    Technology appraisal guidance
    Awaiting development

  41. Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]

    In development Reference number: GID-TA11819 Expected publication date: TBC

    Technology appraisal guidance
    In development

  42. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]

    In development Reference number: GID-TA11694 Expected publication date: TBC

    Technology appraisal guidance
    In development

  43. Donanemab for reducing the risk of mild cognitive impairment in preclinical Alzheimer's disease [ID6675]

    Awaiting development Reference number: GID-TA11876 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  44. Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over ID6542

    In development Reference number: GID-TA11525 Expected publication date:  10 February 2027

    Technology appraisal guidance
    In development

  45. Fianlimab with cemiplimab for untreated unresectable advanced melanoma or adjuvant treatment of completely resected high-risk melanoma [TSID12303]

    Awaiting development Reference number: GID-TA11929 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  46. Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [TSID12299]

    Awaiting development Reference number: GID-TA11930 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  47. Belzutifan for treating advanced pheochromocytoma or paraganglioma [TSID12304]

    Awaiting development Reference number: GID-TA11928 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  48. Artificial intelligence (AI) technologies to help detect prostate cancer on multiparametric (mp) MRI

    In development Reference number: GID-HTE10089 Expected publication date: TBC

    Health technology evaluations
    In development

  49. Digital hearing aids (Provisional title)

    In development Reference number: GID-HTE10079 Expected publication date: TBC

    Health technology evaluations
    In development

  50. Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)

    Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making

    Evidence summary
    Published
    9 June 2016